Circulating tumor DNA minimal residual disease detection of non–small-cell lung cancer treated with curative intent
Circulating tumor DNA (ctDNA) minimal residual disease (MRD) is a powerful biomarker
with the potential to improve survival outcomes for non–small-cell lung cancer (NSCLC) …
with the potential to improve survival outcomes for non–small-cell lung cancer (NSCLC) …
Malignant peripheral nerve sheath tumor: models, biology, and translation
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive, invasive cancer that
comprise around 10% of all soft tissue sarcomas and develop in about 8–13% of patients …
comprise around 10% of all soft tissue sarcomas and develop in about 8–13% of patients …
Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
Abstract People with Li–Fraumeni syndrome (LFS) harbor a germline pathogenic variant in
the TP53 tumor suppressor gene, face a near 100% lifetime risk of cancer, and routinely …
the TP53 tumor suppressor gene, face a near 100% lifetime risk of cancer, and routinely …
Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and src family kinase YES in rhabdomyosarcoma
S Akshintala, RT Sundby, D Bernstein, JW Glod… - Clinical cancer …, 2023 - AACR
Purpose: Antibodies against insulin-like growth factor (IGF) type 1 receptor have shown
meaningful but transient tumor responses in patients with rhabdomyosarcoma (RMS). The …
meaningful but transient tumor responses in patients with rhabdomyosarcoma (RMS). The …
[HTML][HTML] Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA
NP Semenkovich, JJ Szymanski… - … for immunotherapy of …, 2023 - ncbi.nlm.nih.gov
Liquid biopsies using cell-free circulating tumor DNA (ctDNA) are being used frequently in
both research and clinical settings. ctDNA can be used to identify actionable mutations to …
both research and clinical settings. ctDNA can be used to identify actionable mutations to …
Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA
Malignant peripheral nerve sheath tumor (MPNST), an aggressive soft-tissue sarcoma,
occurs in people with neurofibromatosis type 1 (NF1) and sporadically. Whole-genome and …
occurs in people with neurofibromatosis type 1 (NF1) and sporadically. Whole-genome and …
Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients
Circulating tumor DNA (ctDNA) sensitivity remains subpar for molecular residual disease
(MRD) detection in bladder cancer patients. To remedy this problem, we focused on the …
(MRD) detection in bladder cancer patients. To remedy this problem, we focused on the …
Combined low-pass whole genome and targeted sequencing in liquid biopsies for pediatric solid tumors
We designed a liquid biopsy (LB) platform employing low-pass whole genome sequencing
(LP-WGS) and targeted sequencing of cell-free (cf) DNA from plasma to detect genome-wide …
(LP-WGS) and targeted sequencing of cell-free (cf) DNA from plasma to detect genome-wide …
Update on pediatric cancer surveillance recommendations for patients with neurofibromatosis type 1, noonan syndrome, CBL syndrome, Costello syndrome, and …
MR Perrino, A Das, SR Scollon, SG Mitchell… - Clinical Cancer …, 2024 - aacrjournals.org
Abstract Neurofibromatosis type 1 (NF1), Noonan syndrome, and related syndromes,
grouped as RASopathies, result from dysregulation of the RAS-MAPK pathway and …
grouped as RASopathies, result from dysregulation of the RAS-MAPK pathway and …
The current status of cell‐free human papillomavirus DNA as a biomarker in cervical cancer and other HPV‐associated tumors: A review
L Sivars, K Palsdottir… - … Journal of Cancer, 2023 - Wiley Online Library
Tumor cells release fragments of their DNA into the circulation, so called cell‐free tumor
DNA (ctDNA), allowing for analysis of tumor DNA in a simple blood test, that is, liquid biopsy …
DNA (ctDNA), allowing for analysis of tumor DNA in a simple blood test, that is, liquid biopsy …